AMAG PHARMACEUTICALS, INC.
AMAG PHARMACEUTICALS, INC. (AMAG): 3 pipeline candidates · ~14 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
14.0 months
D/E 1.87 · 1% dilution
Lead: Phase 2/Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for AMAG PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$98.5M
Quarterly Burn
$42.8M
Runway
14.0 mo
Revenue
$93.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| amag-423 | Phase 2/Phase 3 |
| ciraparantag | Phase 2 |
| ferumoxytol | Phase 3 |
Frequently asked questions
How many drug candidates are in AMAG PHARMACEUTICALS, INC.'s pipeline?
AMAG PHARMACEUTICALS, INC. (AMAG) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AMAG PHARMACEUTICALS, INC.'s lead drug candidate?
AMAG PHARMACEUTICALS, INC.'s most advanced tracked candidate is amag-423 (Phase 2/Phase 3) for Severe Preeclampsia.
What is AMAG PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AMAG PHARMACEUTICALS, INC. has approximately 14.0 months of cash runway.
Who is the CEO of AMAG PHARMACEUTICALS, INC.?
On April is the chief executive officer of AMAG PHARMACEUTICALS, INC. (AMAG).
Get the full picture on AMAG PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.